Related Experiment Video

Updated: May 3, 2026

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

10.4K

Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society

Steven H Abman, Georg Hansmann, Stephen L Archer

    Circulation
    |November 5, 2015
    PubMed

    Insights

    Pediatric pulmonary hypertension (PH) poses significant risks, but lacks expert guidelines. This joint American Heart Association and American Thoracic Society effort provides crucial recommendations for diagnosing, evaluating, and treating PH in children.

    Area of Science:

    • Pediatric Cardiology
    • Pulmonology
    • Critical Care Medicine

    Background:

    • Pulmonary hypertension (PH) in children is linked to severe cardiac, pulmonary, and systemic conditions, causing significant illness and death.
    • Existing pediatric PH care is hindered by a lack of expert consensus guidelines.
    • This gap impacts the effective management of PH in neonates, infants, and children.

    Purpose of the Study:

    • To develop evidence-based consensus guidelines for the diagnosis, evaluation, and treatment of pediatric pulmonary hypertension.
    • To address the critical need for standardized care approaches in pediatric PH.
    • To synthesize current literature and expert opinion for clinical recommendations.

    Main Methods:

    • A joint panel of experienced clinicians and clinician-scientists was convened by the American Heart Association and American Thoracic Society.
    • Extensive reviews of the existing scientific literature on pediatric PH were conducted.
    • Formal scoring methods were used to develop and formalize recommendations.

    Main Results:

    • The publication presents comprehensive recommendations for pediatric pulmonary hypertension care.
    • The guidelines cover diagnosis, evaluation, and treatment strategies.
    • This work establishes a consensus framework for managing pediatric PH.

    Conclusions:

    • The developed guidelines offer a critical resource for clinicians managing pediatric pulmonary hypertension.
    • Implementation of these recommendations is expected to improve patient outcomes and reduce morbidity and mortality.
    • This collaborative effort establishes a foundation for future advancements in pediatric PH care.

    Keywords:
    AHA Scientific Statementsbronchopulmonary dysplasiacongenital diaphragmatic herniacongenital heart diseasegeneticspersistent pulmonary hypertension of the newbornsickle cell disease

    More Related Videos

    Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection08:15

    Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

    Published on: January 31, 2020

    9.3K
    Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs08:18

    Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

    Published on: July 27, 2022

    1.7K

    Related Concept Videos

    Pulmonary Hypertension: Classification and Pathogenesis01:30

    Pulmonary Hypertension: Classification and Pathogenesis

    Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
    There are various classifications for PH, each relating to different underlying causes and also...
    906
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
    615
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    689
    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

    Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
    Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
    817
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    632
    Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

    Hypertension III: Clinical Manifestations and Diagnostic Studies

    Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
    886